Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 16,839 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Recruiting Phase 3 Interventional

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Not applicable Interventional Results available

Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers

NCT05203471
View directory record Official record
Conditions
Diabetic Foot, Diabetic Ulcer of Left Foot, Diabetic Ulcer of Right Foot, Amputation
Interventions
integrated care model
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

NCT03167957
View directory record Official record
Conditions
Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB)
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005, pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Suspended Not applicable Interventional

Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer

NCT07268092
View directory record Official record
Conditions
Head and Neck Cancer, Neck Dissection, Postoperative Complications
Interventions
Porcine Extracellular Matrix Nerve Wrap (AxoGuard Nerve Protector™)
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 23, 2026, 7:25 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

NCT07736937
View directory record Official record
Conditions
Ovarian Cancer
Interventions
TUB-040 + Carbo + BEV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Los Angeles, California • East Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Terminated No phase listed Observational Results available

Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse

NCT00099372
View directory record Official record
Conditions
Prolapse, Urinary Incontinence
Interventions
Not listed
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Not applicable Interventional

Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)

NCT04227977
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
JuxtaFlow System
Device
Lead sponsor
3ive Labs
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Cleveland, Ohio • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

NCT03972657
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Active, not recruiting Not applicable Interventional

Clinical Study of External Electrical Stimulation for Male Incontinence

NCT06620419
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Perineal-applied electrical stimulation
Device
Lead sponsor
Elidah, Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroe, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of High Altitude on AMPK Activation

NCT02391519
View directory record Official record
Conditions
Pregnancy, IUGR, Preeclampsia
Interventions
Collection of myometrial, cord blood, and placental tissue samples
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Phase 1 Interventional

Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

NCT02096965
View directory record Official record
Conditions
Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Not applicable Interventional

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

NCT01442051
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Acute Normovolemic Hemodilution
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 23, 2026, 7:25 AM EDT
Terminated Phase 2 Interventional

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interpersonal Psychotherapy in Adolescents With Polycystic Ovary Syndrome

NCT06056453
View directory record Official record
Conditions
Interpersonal Psychotherapy, Polycystic Ovary Syndrome
Interventions
Interpersonal Psychotherapy
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Not applicable Interventional

EASE: The Materna Prep Pivotal Study

NCT03973281
View directory record Official record
Conditions
Vaginal Delivery, Pelvic Organ Prolapse
Interventions
Materna Prep Device, Standard of Care (SOC)
Device · Other
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Greenbrae, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 7:25 AM EDT
Completed Phase 3 Interventional Results available

Traditional Clomiphene Citrate Administration vs. Stair-step Approach

NCT01008319
View directory record Official record
Conditions
Ovulatory Dysfunction, Anovulation, Ovulation Induction
Interventions
clomiphene citrate
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 23, 2026, 7:25 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

NCT04456530
View directory record Official record
Conditions
Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
Interventions
Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection
Drug · Other
Lead sponsor
The Stone Research Foundation for Sports Medicine and Arthritis
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 23, 2026, 7:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children

NCT00392730
View directory record Official record
Conditions
Parenteral Nutrition, Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
Interventions
Remove Mn from PN if evidence of increased brain Mn on MRI
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
30 Days to 6 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 23, 2026, 7:25 AM EDT
Recruiting Phase 2 Interventional

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Margate, Florida • Pompano Beach, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 7:25 AM EDT